In conclusion, the studies presented here show that the use of bsAb targeting VISTA and PD-L1 antibodies results in a higher level of tumor cell lysis in pancreatic, breast and endometrial cancers than monospecific antibodies and their combination. Here, VSIR is linked to endometrial cancer.